Patrick G. Pilié, M.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Genitourinary Medical Oncology, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2011 | Duke University School of Medicine, Durham, North Carolina, US, MD |
| 2006 | University of Georgia, Athens, Georgia, US, Genetics, BS |
Postgraduate Training
| 2015-2018 | Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011-2014 | Clinical Residency, Internal Medicine, University of Michigan, Ann Arbor, Michigan |
Licenses & Certifications
| 2026 | DEA |
| 2020 | Texas Medical License |
| 2018 | American Board of Internal Medicine - Medical Oncology |
| 2014 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Genitourinary Medical Oncology, The Univ. of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2025
Instructor, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2019
Hospitalist, Hematology & SCT, University of Michigan, Ann Arbor, MI, 2014 - 2015
Administrative Appointments/Responsibilities
Director, Genitourinary Medical Oncology, Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present
Director for Genitourinary Medical Oncology Prostate Genetics Clinic, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019
Co-director for Genitourinary Medical Oncology Rotation, Hematology Oncology Fellowship Program, Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, 2017
Other Professional Positions
HHMI Medical Research Fellow, Duke University, Durham, NC, 2009 - 2010
Post-Baccalaureate Research Fellow, Duke University, Durham, NC, 2006 - 2007
Extramural Institutional Committee Activities
Voting Member, Genomics Testing Priority Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Birdie for Buddies Prostate Cancer Grant Review Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Birdie for Buddies Prostate Cancer Grant Review Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Department Representative, Charge of the Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2022 - 2025
Voting Member, Clinical Effectiveness Subcommittee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Honors & Awards
| 2021 | 2021 Pinnacle of Excellence Award for Patient Experience, Press Ganey |
| 2020 | ASCO Career Development Award, American Society of Clinical Oncology |
| 2019 | Young Investigator Award, Prostate Cancer Foundation |
| 2019 | Prostate Cancer SPORE Career Enhancement Award, The University of Texas MD Anderson Cancer Center |
| 2018 | Merit Award Recipient & Rapid-fire Oral Presentation, GU ASCO |
| 2018 | Young Investigator Award, Kidney Cancer Association |
| 2018 | Methods in Clinical Cancer Research Workshop, AACR/ASCO |
| 2017 - 2019 | Loan Repayment Program Grant for Clinical Research, National Institute of Health |
| 2017 | Top Recipient for Fellows Research, Texas Society of Clinical Oncology |
| 2017 | Molecular Biology in Clinical Oncology Workshop, American Association of Cancer Research |
| 2014 | Plenary Oral Presentation Winner, University of Michigan IM Research Symposium |
| 2012 - 2013 | Making A Difference Patient Care Award, University of Michigan |
| 2010 | Alpha-Omega-Alpha Research Award: Best Basic Science Presentation, Duke University |
| 2010 | Medical Student Research Grant, Howard Hughes Medical Institute |
| 2006 | Graduated Summa Cum Laude with research scholar distinction, University of Georgia |
| 2005 | Summer Undergraduate Research Program, New York University School of Medicine |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2024. Best Examples of Systematic Agent Decisions that Balance Quality and Quantity of Life. Invited. AUA 2024 Meeting. San Antonio, Texas, US.
- 2024. Co-Targeting Androgen Receptor Signaling and DNA Damage Response in Castrate Sensitive Prostate Cancer. Invited. 2024 Multi-Institutional Prostate Cancer Program Retreat. Los Angeles, California, US.
- 2023. Targeting the intersection of DNA Damage Response and Androgen Signaling in Prostate Cancer. Invited. Molecular and Cellular Oncology Distinguished Seminar Series. Houston, Texas, US.
- 2023. Targeted Treatments and Clinical Trials for Men with BRCA1/2 Deficient Prostate Cancers. Conference. Chicago, IL, US.
- 2023. Genetics/Counseling in Urologic Cancers. Conference. Genetics/Counseling in Urologic Cancers. Austin, TX, US.
- 2023. Ataxia-telangiectasia mutated loss of function displays variant and tissue specific differences across tumor types. Conference. AACR Annual Meeting, US.
- 2022. Targeting DNA Damage Response in Prostate Cancer. Conference. Targeting DNA Damage Response in Prostate Cancer. San Antonio, TX, US.
- 2020. Understanding Somatic & Germline Alterations to Fine-Tune DDR Therapy. Conference. Understanding Somatic & Germline Alterations to Fine-Tune DDR Therapy. Boston, MA, US.
- 2019. Inhibitors of Ataxia-Telangiectasia Related (ATR) protein lead to innate immune pathway activation and enhanced response to immune therapy in prostate cancer. Conference. Inhibitors of Ataxia-Telangiectasia Related (ATR) protein lead to innate immune pathway activation and enhanced response to immune therapy in prostate cancer. National Harbor, MD, US.
- 2018. Functional Biomarkers of Homologous Repair Deficiency to Guide Novel DNA Damage Repair Targeted Therapy in Clear Cell Renal Cell Carcinoma. Conference. Functional Biomarkers of Homologous Repair Deficiency to Guide Novel DNA Damage Repair Targeted Therapy in Clear Cell Renal Cell Carcinoma. Chicago, IL, US.
- 2018. Replication Stress Response Deficiency Predicts Response to Immune Therapy in Advanced Clear Cell Renal Cell Carcinoma. Conference. Replication Stress Response Deficiency Predicts Response to Immune Therapy in Advanced Clear Cell Renal Cell Carcinoma. Chicago, IL, US.
- 2018. Homologous Repair Deficiency in VHL-mutated clear cell Renal Cell Carcinoma. Conference. Homologous Repair Deficiency in VHL-mutated clear cell Renal Cell Carcinoma. San Francisco, IL, US.
- 2017. Genomic Instability and DNA Damage Repair in clear cell Renal Cell Carcinoma. Conference. Genomic Instability and DNA Damage Repair in clear cell Renal Cell Carcinoma. Chicago, IL, US.
- 2016. Pilot Study of Dovitinib in Patients with Von Hippel Lindau Disease. Conference. Pilot Study of Dovitinib in Patients with Von Hippel Lindau Disease. San Francisco, CA, US.
- 2015. Identification of Germline Mutations in Men with Early-Onset Prostate Cancer. Conference. Identification of Germline Mutations in Men with Early-Onset Prostate Cancer. Chicago, IL, US.
- 2014. Germline Mutations in Men with Multiple Primary Malignancies from a Hereditary Prostate Cancer Cohort. Conference. Germline Mutations in Men with Multiple Primary Malignancies from a Hereditary Prostate Cancer Cohort. San Diego, CA, US.
- 2010. Proteomic Profiling of Early Mammary Carcinogenesis: Targeting Dysregulated Protein Pathways w/ Combination Tailored Therapeutics. Conference. Proteomic Profiling of Early Mammary Carcinogenesis: Targeting Dysregulated Protein Pathways w/ Combination Tailored Therapeutics. San Francisco, CA, US.
- 2007. The Frequency of Loss of Heterozygosity and Microsatellite Instability of RARB2 and p16 in Random Periareolar Fine Needle Aspiration Samples of Women at High Risk of Developing Breast Cancer. Conference. The Frequency of Loss of Heterozygosity and Microsatellite Instability of RARB2 and p16 in Random Periareolar Fine Needle Aspiration Samples of Women at High Risk of Developing Breast Cancer. Breckenridge, CO, US.
International Presentations
- 2017. Germline Genetic Variants in Men with Prostate Cancer and One or More Additional Cancers. Conference. Germline Genetic Variants in Men with Prostate Cancer and One or More Additional Cancers. Cancun, MX.
Formal Peers
- 2023. Targeted Treatments and Clinical Trials for Men with BRCA1/2 Deficient Prostate Cancers. Invited. Chicago, IL, US.
Grant & Contract Support
| Date: | 2027 - 2030 |
| Title: | Intercepting Neuroendocrine Transition in Prostate Cancer |
| Funding Source: | Department of War |
| Role: | Collaborator |
| ID: | FP00031598 |
| Date: | 2027 - 2029 |
| Title: | Intercepting Neuroendocrine Transition in Prostate Cancer Using Hyperpolarized MRI and PARP Inhibition |
| Funding Source: | NIH |
| Role: | Co-I |
| Date: | 2026 - 2031 |
| Title: | HEALTH4Families: A weight management and health behavior intervention for families with genetic predisposition to cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00028952 |
| Date: | 2025 - 2028 |
| Title: | Artificial intelligence for early identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | PC240532P1 |
| Date: | 2025 - 2028 |
| Title: | Targetable DNA Damage Response Pathways Drive Heterogeneity in Patient Outcomes to Anti-Androgen Therapy in Advanced Hormone Naïve Prostate Cancer |
| Funding Source: | DOD |
| Role: | PI |
| ID: | PC240628 |
| Date: | 2025 - 2030 |
| Title: | Non-Invasive Biomarkers for Patient Selection of Combination PARP Inhibition and Androgen Receptor Signaling Inhibition in Hormone-Sensitive Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 |
| Date: | 2025 - 2030 |
| Title: | Comprehensive Clinical and Co-Clinical Characterization of Prostate Cancers Transitioning from Treatable to Lethal Phenotypes to Inform Individualized Treatment Strategy |
| Funding Source: | Prostate Cancer Foundation |
| Role: | Co-I |
| Date: | 2025 - 2030 |
| Title: | Increasing Uptake of Germline Genetic Testing among Prostate Cancer Patients in a Diverse Safety Net Hospital |
| Funding Source: | CPRIT-ECIA |
| Role: | PI |
| ID: | RP250475 |
| Date: | 2023 - 2028 |
| Title: | Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration- Resistant Prostate Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA281727-02 |
| Date: | 2021 - 2028 |
| Title: | 2020-1039: Phase II Trial of Primary Radiotherapy with Androgen Ablation with or Without Adjuvant Niraparib for Selected High-Risk Local Regional Prostate Cancer |
| Funding Source: | Janssen Scientific Affairs LLC |
| Role: | PI |
| ID: | NCT04947254 |
| Date: | 2020 - 2023 |
| Title: | Targeting the Replication Stress Response to Induce Anti-Cancer Immunity in Advanced Solid Malignancies |
| Funding Source: | Conquer Cancer Foundation - CDA |
| Role: | PI |
| Date: | 2019 - 2023 |
| Title: | Rational Combinations to Target the Replication Stress Response in Prostate Cancer |
| Funding Source: | Prostate Cancer Foundation - Young Investigator Award |
| Role: | PI |
| ID: | 19Youn17 |
| Date: | 2019 - 2022 |
| Title: | Targeting the Replication Stress Response in Advanced Prostate Cancer |
| Funding Source: | NIH/MD Anderson – Career Enhancement Program |
| Role: | CEP PI |
| ID: | P50 CA140388 |
| Date: | 2019 - 2025 |
| Title: | 2018-1152: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer (NCT03748641) |
| Funding Source: | Janssen Research and Development LLC |
| Role: | PI |
| ID: | NCT03748641 |
| Date: | 2018 - 2021 |
| Title: | Identifying and Targeting DNA Damage Response Deficiency in clear cell Renal Cell Carcinoma |
| Funding Source: | Kidney Cancer Association- Young Investigator Award |
| Role: | PI |
| ID: | YIA |
| Date: | 2017 - 2023 |
| Title: | 2016-0735: A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies |
| Funding Source: | Janssen Pharmaceuticals Inc |
| Role: | PI |
| ID: | NCT02854436 |
| Date: | 2017 - 2019 |
| Title: | Loan Repayment Program Grant for Clinical Research |
| Funding Source: | NIH |
| Role: | Trainee |
| Date: | 2014 - 2015 |
| Title: | Prostate SPORE Pilot Project |
| Funding Source: | University of Michigan |
| Role: | Co-PI |
Selected Publications
Peer-Reviewed Articles
- Singh, P, D’Rozario, R, Chakraborty, B, Meher, S, Raychaudhuri, D, Tannir, AJ, Li, Y, Majumdar, A, Hawkins, J, Xiong, Y, Lorenzi, PL, Sharma, P, Akdemir, KC, Pilie, PG, Jain, A, Lee, B, Goswami, S. Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer. Nature communications 17(1), 2026. e-Pub 2026. PMID: 41501085.
- Subramani E, Pilie PG, Slack-Tidwell R, Viscuse PV, Kuang X, Kandasamy T, Awad D, Han JJ, Huang L, Peterson CB, Zurita AJ, Subudhi SK, Corn PG, Soundararajan R, Shepherd P, Piyarathna B, Putluri V, Putluri N, Sreekumar A, Wang Y, Zoubeidi A, Mahmud I, Martinez SA, Tan L, Lorenzi PL, Basu S, Jindal S, Sharma P, Logothetis CJ, Thompson TC, Frigo DE, Aparicio AM. Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers. iScience 29(6):116184, 2026. e-Pub 2026. PMID: 42291217.
- Aparicio AM, Pilie PG. Impact of adding hormone therapy to postoperative radiotherapy in prostate cancer. Lancet 407(10533):1030-1031, 2026. e-Pub 2026. PMID: 41765028.
- Venkatesh N, Chauhan PK, Mukhida SS, Grewal K, Aparicio A, Pilie PG, Subudhi SK, Corn PG, Sachdeva A, Desai M, Siddiqui BA, Zurita AJ, Pain D, Gregg JR, Frigo DE, Logothetis CJ, Msaouel P, Koutroumpakis E, Hahn AW. Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone Therapy. JCO Oncol Pract:OP2500506, 2025. e-Pub 2025. PMID: 41202201.
- Sherry AD, Siddiqui BA, Haymaker C, Fellman BM, Medina-Rosales MN, Bathala TK, Wang S, Liu S, Seo A, Hara K, Lu H, Troncoso P, Chun SG, Ha CS, Mayo LL, Mok H, Park RJ, Chapin BF, Phillips RM, Deek MP, Kovitz CA, Aparicio A, Zurita AJ, Pilie PG, Cohen L, Choi SL, Reuben A, Tran PT, Corn PG, Subudhi SK, Tang C. Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial. Eur Urol 88(5):496-509, 2025. e-Pub 2025. PMID: 40750497.
- Sharma K, Wilson DA, Wang Y, Haider S, Bhatlapenumarthi V, Boiarsky D, Cipriaso JM, Yermakov L, Dutta R, Vashisth M, Coleman IM, Bankhead A, Jadhav SK, Neupane B, Taylor BW, Morrissey C, Schweitzer MT, Montgomery RB, Rao S, Nevalainen MT, Nelson AA, Antonarakis ES, Pilie PG, Berchuk JE, Zarrabi KK, Pritchard CC, Kthari A, Chen HZ, George B, Kurzrock R, Ha G, Nelson PS, Auer PL, Banerjee A, Kilari D, De Sarkar N. CHIMERA-DDR: A Machine Learning Framework for Classifying Heterogeneous Mismatch-Repair and Homologous-Recombination Deficiency Patterns in Prostate Cancer. bioRxiv, 2025. e-Pub 2025. PMID: 41278905.
- Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis 28(3):802-808, 2025. e-Pub 2025. PMID: 39019979.
- Hsieh KL, Zhang K, Chu Y, Yu L, Li X, Hu N, Kawosa I, Pilie PG, Bhattacharya PK, Zhi D, Jiang X, Zhao Z, Dai Y. iGTP: learning interpretable cellular embedding for inferring biological mechanisms underlying single-cell transcriptomics. Brief Bioinform 26(3), 2025. e-Pub 2025. PMID: 40551620.
- Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, Hahn AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer 31(12), 2024. e-Pub 2024. PMID: 39324992.
- Hsieh KL, Zhang K, Chu Y, Yu L, Li X, Hu N, Kawosa I, Pilie PG, Bhattacharya PK, Zhi D, Jiang X, Zhao Z, Dai Y. iGTP: Learning interpretable cellular embedding for inferring biological mechanisms underlying single-cell transcriptomics. medRxiv, 2024. e-Pub 2024. PMID: 39649598.
- Hsieh KL, Chu Y, Li X, Pilie PG, Dai Y. scEMB: Learning context representation of genes based on large-scale single-cell transcriptomics. bioRxiv, 2024. e-Pub 2024. PMID: 39386549.
- Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilie PG, Davis JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int 134(3):449-458, 2024. e-Pub 2024. PMID: 38837608.
- Aparicio AM, Tidwell RSS, Yadav SS, Chen JS, Zhang M, Liu J, Guo S, Pilie PG, Yu Y, Song X, Vundavilli H, Jindal S, Zhu K, Viscuse PV, Lebenthal JM, Hahn AW, Soundararajan R, Corn PG, Zurita-Saavedra A, Subudhi SK, Zhang J, Wang W, Huff C, Troncoso P, Allison JP, Sharma P, Logothetis CJ. A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 30(13):2751-2763, 2024. e-Pub 2024. PMID: 38683200.
- Pilie PG, Giuliani V, Wang WL, McGrail DJ, Bristow CA, Ngoi NYL, Kyewalabye K, Wani KM, Le H, Campbell E, Sanchez NS, Yang D, Gheeya JS, Goswamy RV, Holla V, Shaw KR, Meric-Bernstam F, Liu CY, Ma X, Feng N, Machado AA, Bardenhagen JP, Vellano CP, Marszalek JR, Rajendra E, Piscitello D, Johnson TI, Likhatcheva M, Elinati E, Majithiya J, Neves J, Grinkevich V, Ranzani M, Luzarraga MR, Boursier M, Armstrong L, Geo L, Lillo G, Tse WY, Lazar AJ, Kopetz SE, Geck Do MK, Lively S, Johnson MG, Robinson HMR, Smith GCM, Carroll CL, Di Francesco ME, Jones P, Heffernan TP, Yap TA. Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types. Clin Cancer Res 30(10):2121-2139, 2024. e-Pub 2024. PMID: 38416404.
- Azad, A, Voskoboynik, M, Joshua, AM, Weickhardt, AJ, Sankey, P, Pacey, S, Heath, EI, Krieger, L, Horvath, L, Pilie, PG, Womersley, L, Linardopoulos, S, Moorthy, G, Zhou, T, Brown, J, Paula, Bd, Lukacs, E, Hudson, A. PETRANHA. Journal of Clinical Oncology 42(4), 2024. e-Pub 2024.
- Viscuse, PV, Slack Tidwell, RS, Zhang, M, Rohra, P, Zhu, K, San Lucas, FA, Konnick, E, Pilie, PG, Siddiqui, BA, Logothetis, CJ, Corn, P, Subudhi, SK, Pritchard, CC, Soundararajan, R, Aparicio, A. Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers 15(24), 2023. e-Pub 2023. PMID: 38136389.
- Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Project BJ, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, Mcmahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, MÉ P, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Butler EN, Mohler JL, Taylor JA, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Pilie P, Yu Y, Bohlender RJ, Gu J, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Brenner H, Chen X, Holleczek B, Schöttker B, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet 55(12):2065-2074, 2023. e-Pub 2023. PMID: 37945903.
- Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
- Geng C, Zhang MC, Manyam GC, Vykoukal JV, Fahrmann JF, Peng S, Wu C, Park S, Kondraganti S, Wang D, Robinson BD, Loda M, Barbieri CE, Yap TA, Corn PG, Hanash S, Broom BM, Pilié PG, Thompson TC. SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor-induced growth suppression. Clin Cancer Res 29(21):4464-4478, 2023. e-Pub 2023. PMID: 37581614.
- Liu XD, Zhang YT, McGrail DJ, Zhang X, Lam T, Hoang A, Hasanov E, Manyam G, Peterson CB, Zhu H, Kumar SV, Akbani R, Pilie PG, Tannir NM, Peng G, Jonasch E. SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma. Clin Cancer Res 29(19):4002-4015, 2023. e-Pub 2023. PMID: 37527013.
- Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol 9(6):825-834, 2023. e-Pub 2023. PMID: 37022702.
- McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY. Validation of cancer-type dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol 33(11):1204-1206, 2022. e-Pub 2022. PMID: 35926816.
- Ngoi, NY, Pilie, PG, Piha-Paul, SA, Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Rodon Ahnert, J, Subbiah, V, Tsimberidou, AM, Salguero, C, Brown, CV, Hoadley, WE, Johnson, A, Yuan, Y, Westin, SN, Meric-Bernstam, F, Yap, TA. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial. European Journal of Cancer 174:S10, 2022. e-Pub 2022.
- Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Laberiano Fernández C, Lorenzini D, Hoang A, Lu W, Soto LMS, Wistuba II, Xu M, Song X, Shepherd PDA, Navone NM, Tidwell RSS, Lozano G, Logothetis C, Zhang J, Long JP, Estecio MR, Tzelepi V, Aparicio AM. Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. Cancers (Basel) 14(13), 2022. e-Pub 2022. PMID: 35805010.
- Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilié PG, Yap TA, Kopetz S, Sander C, Korkut A. Precision combination therapies based on recurrent oncogenic co-alterations. Cancer Discov 12(6):1542-1559, 2022. e-Pub 2022. PMID: 35412613.
- Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K, investigators G. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol 23(3):362-373, 2022. e-Pub 2022. PMID: 35131040.
- Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilié PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol 6:e2100267, 2022. e-Pub 2022. PMID: 35108036.
- McGrail DJ, Pilié PG, Dai H, Lam TNA, Liang Y, Voorwerk L, Kok M, Zhang XH, Rosen JM, Heimberger AB, Peterson CB, Jonasch E, Lin SY. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci Transl Med 13(617):eabe6201, 2021. e-Pub 2021. PMID: 34705519.
- Tang Z, Pilié PG, Geng C, Manyam GC, Yang G, Park S, Wang D, Peng S, Wu C, Peng G, Yap TA, Corn PG, Broom BM, Thompson TC. ATR inhibitor-induced CDK1-SPOP axis destabilizes PD-L1 and enhances cytotoxicity in prostate cancer. Clin Cancer Res 27(17):4898-4909, 2021. e-Pub 2021. PMID: 34168048.
- Wu C, Peng S, Pilié PG, Geng C, Park S, Manyam GC, Lu Y, Yang G, Tang Z, Kondraganti S, Wang D, Hudgens CW, Ledesma DA, Marques-Piubelli ML, Torres-Cabala CA, Curry JL, Troncoso P, Corn PG, Broom BM, Thompson TC. PARP and CDK4/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer. Mol Cancer Ther 20(9):1680-1691, 2021. e-Pub 2021. PMID: 34158347.
- McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY. Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. Ann Oncol 32(9):1194-1197, 2021. e-Pub 2021. PMID: 34166757.
- Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS, Pilie P, Sonbol MB, Alhalabi O. Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016. JAMA Netw Open 4(8):e2119568, 2021. e-Pub 2021. PMID: 34351403.
- McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32(5):661-672, 2021. e-Pub 2021. PMID: 33736924.
- Pilié PG, George A, Yap TA. Patient Selection Biomarker Strategies for PARP Inhibitor Therapy. Ann Oncol. e-Pub 2020. PMID: 33011228.
- Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 37(5):720-734.e13, 2020. e-Pub 2020. PMID: 32359397.
- Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun 11(1):2135, 2020. e-Pub 2020. PMID: 32358509.
- Pilie P, Jonasch E. Durable complete response in renal cell carcinoma clinical trials. Lancet 393(10189):2362-2364, 2019. e-Pub 2019. PMID: 31079937.
- Pilié PG, Jonasch E. SET-ing the stage for PI3Kβ inhibitor sensitivity in clear cell renal cell carcinoma. Oncotarget 10(16):1540-1541, 2019. e-Pub 2019. PMID: 30899419.
- Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, Robichaux CC, Villarreal MF, Weldon JA, Woodson AH, Pilie PG, Fuller GN, Waguespack SG, Matin SF. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol 19(10):1351-1359, 2018. e-Pub 2018. PMID: 30236511.
- Pilié PG, Cooney KA. Broadening the View of Germline Mutations in Kidney Cancer. JAMA Oncol 4(9):1235-1236, 2018. e-Pub 2018. PMID: 29978199.
- Pilié P, Hasanov E, Matin SF, Woodson AHH, Marcott VD, Bird S, Slack RS, Fuller GN, McCutcheon IE, Jonasch E. Pilot study of dovitinib in patients with von Hippel-Lindau disease. Oncotarget 9(34):23390-23395, 2018. e-Pub 2018. PMID: 29805741.
- Pilié PG, LoRusso PM, Yap TA. Precision Medicine: Progress, Pitfalls, and Promises. Mol Cancer Ther 16(12):2641-2644, 2017. e-Pub 2017. PMID: 29203693.
- Pilié PG, Johnson AM, Hanson KL, Dayno ME, Kapron AL, Stoffel EM, Cooney KA. Germline genetic variants in men with prostate cancer and one or more additional cancers. Cancer 123(20):3925-3932, 2017. e-Pub 2017. PMID: 28657667.
- Pilié PG, Jonasch E. Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. Kidney Cancer 1(1):57-64, 2017. e-Pub 2017. PMID: 30334005.
- Pilié PG, Jonasch E, McCutcheon IE. Key considerations in the treatment of von Hippel-Lindau disease. Future Oncol 12(15):1755-8, 2016. e-Pub 2016. PMID: 27020706.
- Pilie PG, Giri VN, Cooney KA. HOXB13 and other high penetrant genes for prostate cancer. Asian J Androl 18(4):530-2, 2016. e-Pub 2016. PMID: 27034017.
- Bowie M, Pilie P, Wulfkuhle J, Lem S, Hoffman A, Desai S, Petricoin E, Carter A, Ambrose A, Seewaldt V, Yu D, Ibarra Drendall C. Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. World J Clin Oncol 6(6):299-311, 2015. e-Pub 2015. PMID: 26677444.
- Pilie P, Werbel WA, Riddell J, Shu X, Schaubel D, Gregg KS. Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes. Transpl Infect Dis 17(4):551-7, 2015. e-Pub 2015. PMID: 26059180.
- Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF, Wulfkuhle J, Liotta LA, Lem S, Baker JC, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat 132(2):487-98, 2012. e-Pub 2012. PMID: 21647677.
- Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF, Wulfkuhle JD, Liotta LA, Lem S, Baker JC, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL. Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiol Biomarkers Prev 20(3):476-82, 2011. e-Pub 2011. PMID: 21242333.
- Vasilatos SN, Broadwater G, Barry WT, Baker JC, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 18(3):901-14, 2009. e-Pub 2009. PMID: 19258476.
- Baker JC, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL. ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev 17(8):1884-90, 2008. e-Pub 2008. PMID: 18708376.
- Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC, Ibarra C, Brander DM, Paisie C, Case NR, Gauthier M, Reynolds PA, Dietze E, Ostrander J, Scott V, Wilke LG, Yee L, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Tlsty TD, Seewaldt VL. Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res 13(22 Pt 1):6834-41, 2007. e-Pub 2007. PMID: 18006786.
Review Articles
- Ngoi NYL, Pilie PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA. Targeting ATR in patients with cancer. Nat Rev Clin Oncol 21(4):278-293, 2024. e-Pub 2024. PMID: 38378898.
- Venkatesh, N, Tidwell, R, Yu, Y, Aparicio, A, Zurita-Saavedra, A, Subudhi, SK, Siddiqui, BA, Gregg, JR, Corn, P, Msaouel, P, Koutroumpakis, E, McQuade, JL, Frigo, DE, Pilie, PG, Logothetis, CJ, Huff, C, Hahn, AW. Association of inherited steroidogenic genotype with body composition changes after androgen signaling inhibition (ASI) in men with biochemical recurrent (BCR), hormone-sensitive prostate cancer (HSPC). Journal of Clinical Oncology 42:108, 2024. e-Pub 2024.
- Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA. PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clin Cancer Res 25(13):3759-3771, 2019. e-Pub 2019. PMID: 30760478.
- Stewart RA, Pilié PG, Yap TA. Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Res 78(24):6717-6725, 2018. e-Pub 2018. PMID: 30498083.
- Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. e-Pub 2018. PMID: 30356138.
Editorials
- Logothetis, CJ, Pilie, PG. Putting Precision Medicine in Prostate Cancer into Practice. European urology 83(2):121-124, 2023.
Abstracts
- Pilié PG. PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results. Journal of Clinical Oncology 42, 2024.
- Pilie PG, Mcgrail D, Wang WL, Ngoi N, Kyewalabye K, Wani K, Le H, Campbell E, Holla V, Shaw KR, Meric-Bernstam F, Lazar, AJ, Giuliani V, Heffernan T, Yap TA. Ataxia-telangiectasia mutated loss of function displays variant and tissue specific differences across tumor types,. 2023 AACR Annual Meeting, 2023. e-Pub 2023.
- Pilie PG, Slack-Tidwell R, Viscuse PV, Subudhi SK, Corn PG, Tu S, Araujo JC, Zurita AJ, Wang J, Efstathiou E, Deinert J, Logothetis C, Thompson TC, Aparicio A. Randomized phase II study of olaparib (Ola) maintenance following cabazitaxelcarboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC). 2023 ASCO Genitourinary Cancers Symposium, 2023. e-Pub 2023.
- a K, Li X, Kong E, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar J, Luna A, Menter D, Pilié P, Yap T, Kopetz S, Sander C. Precision combination therapies based on recurrent oncogenic co-alterations. 2022 AACR Annual Meeting, 2022. e-Pub 2022.
- Hahn A, Wang X, Efstathiou E, Hwang H, Zurita A, Spetsieris N, Boukovala M, Wang J, Araujo J, Pilié P, Siddiqui B, Subudhi S, Corn P, Aparicio A, Tu S, Logothetis C. Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naïve prostate cancer (M0HNPC). 2022 ASCO Genitourinary Cancers Symposium, 2022. e-Pub 2022.
- Hahn AW, Tidwell R, Surasi DS, Pilie PG, Frigo D, Subudhi SK, Efstathiou E, Zurita AJ, Tu SM, Chapin BF, Fogelman DR, SStarbuck MW, Corn PG, Aparicio A, McQuade JL, Logothetis C. Adiposity and response to androgen signaling inhibition (ASI) in men with metastatic castration-resistant prostate cancer (mCRPC). 2021 Genitourinary Cancers Symposium, 2021. e-Pub 2021.
- Viscuse PV, Zhang M, Liu J, Tidwell R, Subudhi SK, Zurita AJ, Corn PG, Tu SM, Araujo JC, Wang J, Efstathiou E, Wang J, Pilie PG, Troncoso P, Zhang J, Logothetis C, Aparicio A. Outcomes in men with metastatic castrate-resistant prostate cancer treated with early platinum-based chemotherapy following an unsatisfactory response to androgen receptor (AR) inhibition as part of the phase II dynamic allocation modular sequential (DynAMo) trial. 2021 Genitourinary Cancers Symposium, 2021. e-Pub 2021.
- Gheeya JS, Goswamy R, Garmezy B, Pilie PG, Wang W, Lee S, Javle M, Rondon J, Mills Shaw KR, Meric-Bernstam F, Yap TA. Clinical characteristics and therapeutic implications of PALB2 variants in patients with advanced solid tumors. Annals of Oncology (2020), 2020. e-Pub 2020.
- Hahn AW, Tidwell RS, Surasi DS, Msaouel P, Efstathiou E, Zurita- Saavedra AJ, Tu S, McQuade JL, Fogelman D, Starbuck MW, Subudhi SK, Corn P, Pilie PG, Aparicio A, Logothetis C. Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology (2020), 2020. e-Pub 2020.
- Viscuse PV, Zhang M, Liu J, Tidwell RS, Subudhi SK, Zurita AJ, Corn PG, Tu SM, Araujo JC, Wang J, Efstathiou E, Wang J, Pilie PG, Troncoso P, Zhang J, Logothetis C, Aparicio A. Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial. 2020 Genitourinary Cancers Symposium, 2020. e-Pub 2020.
- Garmezy B, Gheeya JS, Thein KZ, Pilie PG, Wang W, Ahnert JR, Shaw KR, Meric-Bernstam F, Yap TA. Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy. 2020 ASCO Virtual Scientific Program, 2020. e-Pub 2020.
- Pilie PG, Gheeya JS, Kyewalabye K, Goswamy RV, Wani KM, Le H, Campbell E, Sanchez NS, Yang D, Garmezy B, Ileana Dumbrava E, Rodon J, Heffernan T, Holla V, Shaw KR, Meric-Bernstam F, Lazar AJ, Wang WL, Yap TA. Identifying functional loss of ATM gene in patients with advanced cancer. 2020 ASCO Virtual Scientific Program, 2020. e-Pub 2020.
- Pace A, Woodson AH, Slack-Tidwell R, Daniels MS, Pilie PG, Litton JK, Hoskovec JM, Jonasch E. Real-world outcomes of genetic testing in a GU genetics clinic and evaluation of current guidelines. 2019 Genitourinary Cancers Symposium, 2019. e-Pub 2019.
- Pilie P, Mcgrail DJ, Lin SY, Jonasch E. Replication stress response deficiency (RSRD) and response to immune therapy in clear cell renal cell carcinoma (ccRCC). 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
- Pilie P, Zhou L, Peterson CB, Peng Y, Peng G, Jonasch E. Homologous repair deficiency in VHL-mutated clear cell renal cell carcinoma. 2018 Genitourinary Cancers Symposium, 2018. e-Pub 2018.
- Pilie P, Peterson CB, Peng Y, Zhou L, Yap TA, Peng G, Jonasch E. Functional biomarkers of homologous repair (HR) deficiency to guide novel DNA damage response targeted therapy in clear cell renal cell carcinoma (ccRCC). 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
- Pilie PG, Zhou L, Tong P, Matin SF, Sircar K, Tamboli P, Karam JA, Wood CG, Hoang A, Jonasch E. Genomic instability and DNA damage repair in clear cell renal cell carcinoma. 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
- Pillie PG, Matin SF, Woodson AH, Marcott VD, Bird S, Slack R, Fuller G, McCutcheon IE, Jonasch E. Pilot study of dovitinib in patients with VHL disease. 2016 Genitourinary Cancers Symposium, 2016. e-Pub 2016.
- Pilie P, Johnson A, Zuhlke K, Okoth L, Tomlins S, Cooney K. Identification of germline mutations in men with early onset prostate cancer. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
- Pilié PG.
Book Chapters
- Aparicio A, Pilie PG, Surasi DS, Choi S, Chapin BF, Logothetis CJ, Corn PG. Neoplasms of the Prostate, 10th Edition. In: Holland-Frei Cancer Medicine. Wiley, 2023.
- Pilie PG, Jonasch E. Hereditary Renal Cell Carcinoma. In: Rare Kidney Tumors: Comprehensive Multidisciplinary Management and Emerging Therapies. Springer, Cham, 2019.
- Pilie PG. Death Receptors and Apoptosis; Cell-cycle Regulation; Tp53; RB1; CDKN2A regulation. In: Handbook of Targeted Cancer Therapy and Immunotherapy. Wolters Kluwer, Lippincott Williams & Wilkins, 2018.
- Pilie PG, Milliron K, Merajver S. DCIS and Hereditary Susceptibility for Breast Cancer. In: Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer. Springer Science & Business Media, 2015.
Patient Reviews
CV information above last modified August 31, 2026